DayTwo

Company Overview

Snapshot

Founded in August 2015 by Lihi Segal and Marius Nacht, DayTwo operates with 11–50 employees. The company has raised a total of $90 million across 7 funding rounds from 11 investors. In August 2024, DayTwo ceased most of its operations.

Business overview

DayTwo is a precision health company focused on individualized solutions for chronic conditions such as diabetes, prediabetes, and clinical obesity. The company leverages high-resolution microbiome analysis and an artificial intelligence-based algorithm to predict blood sugar responses to foods and food combinations. Its clinically proven approach is built upon a proprietary microbiome dataset, one of the largest globally, serving markets in the United States, North America, and Israel within the digital healthcare and digital therapeutics sectors.

Strategic signal

In August 2024, DayTwo ceased most of its operations, marking a significant shift in its trajectory. This development indicates a challenging period for the healthtech startup, signaling to investors and the market that its previous growth strategy was not sustainable, leading to a substantial restructuring of the business.

Company Intelligence Q&A

What is DayTwo's primary focus?

DayTwo focuses on precision nutrition for metabolic diseases, including diabetes, prediabetes, and clinical obesity, using microbiome analysis and AI to predict individual blood sugar responses to food.

When was DayTwo founded and by whom?

DayTwo was founded in August 2015 by Lihi Segal and Marius Nacht.

What was a significant operational change for DayTwo in 2024?

In August 2024, DayTwo ceased most of its operations.

What was a notable event for DayTwo in 2022?

In September 2022, DayTwo laid off dozens of employees, as reported by CTech on September 15, 2022.

Which investors participated in DayTwo's May 2021 funding round?

In May 2021, DayTwo received funding from investors including Poalim Equity and 10D.